Advertisement

Topics

Luminate meets primary endpoint in phase 2b trial for DME

13:57 EDT 9 Aug 2017 | Healio

Allegro Ophthalmics’ phase n2b stage 2 DEL MAR study of Luminate for diabetic macular edema has met its primary endpoint, according to a company press release.The double-masked, placebo-controlled, randomized, multicenter clinical trial had five arms and evaluated Luminate, a first-in-class integrin peptide therapy, as a sequential therapy or in combination with anti-VEGF in 80 patients, the release said.

Original Article: Luminate meets primary endpoint in phase 2b trial for DME

NEXT ARTICLE

More From BioPortfolio on "Luminate meets primary endpoint in phase 2b trial for DME"

Quick Search
Advertisement
 

Relevant Topics

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...